Upamostat, a once-daily oral medicine, was also safe and tolerable in the phase 2 study, meaning the antiviral met its primary endpoint, RedHill said Tuesday. The therapy, also named RHB-107, reduced new severe COVID-19 symptoms by 87.8%, the biotech said. One patient on the drug experienced severe new symptoms compared to four patients in the placebo group.
Opaganib completely inhibited SARS-CoV-2 viral replication as measured after three days incubation in an in vitro model of human bronchial tissue, comparing favorably with remdesivir, the positive control in the study
TEL-AVIV, Israel and RALEIGH, N.C., April 20, 2020, RedHill Biopharma Ltd. (Nasdaq: RDHL) (“RedHill” or the “Company”), a specialty biopharmaceutical company, today announced that it has entered into an agreement with the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH), to provide its investigational drug, RHB-107 (upamostat, WX-671)1, for testing in non-clinical studies for activity against SARS-CoV-2, the virus that causes coronavirus disease (COVID-19).